Genetic Leap, a clinical stage, AI-native biotech company involved in RNA genetic therapeutics, announced on Wednesday that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for GL-IL2-138, a small-molecule modulator of natural interleukin-2 (IL-2).
According to Genetic Leap, IL-2 is a pleiotropic cytokine that regulates the careful homeostatic balance between immune tolerance and activation.
The drug will now be tested in a randomised, double-blind, placebo-controlled phase 1 clinical trial to evaluate its tolerability, pharmacokinetics and pharmacodynamics in humans.
Imaging Biometrics soft closes Phase 1 Ttrial for oral GaM in glioblastoma
Viatris reports MR-139 Phase 3 study in blepharitis did not meet primary endpoint
CorestemChemon partners with ATG Lifetech to provide next-gen preclinical services
EQT agrees to acquire majority stake in Adalvo
Sanofi finalizes acquisition of Blueprint Medicines to expand rare disease and immunology portfolio
Clarity Pharmaceuticals' Co-PSMA trial completes recruitment
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
Actuate Therapeutics advances Ewing Sarcoma trial following positive Phase 1 results
Oxurion secures funding to acquire majority stake in Axiodis CRO
Genetic Leap's GL-IL2-138 receives FDA IND clearance
Amphix Bio's AMFX-200 receives US FDA Orphan Drug Designation to treat acute spinal cord injury
Innovent Biologics' Phase 1 anti-CLDN18.2 ADC (IBI343) results published in Nature Medicine
Hemogenyx wins USD120,000 grant to advance scalable CAR-T manufacturing